Carter's, Inc. (CRI) draws meaningful sell-side coverage as a stock rather than an ETF. Looking at seven individual, attributable targets shows Barclays at $26 (Underweight), Bank of America at $28 (Underperform), Wells Fargo at $30 (Equal-Weight), UBS at $33 (Hold), Goldman Sachs at $38 (Hold), BMO Capital at $40 (Outperform), and Citi at $53 (Buy).
The arithmetic mean of those seven comes to about $35.4, only slightly above the recent share price and therefore not pointing to a strong upside case. Instead, the central target averages the three figures above the current price — Citi's $53, BMO's $40, and Goldman Sachs' $38 — which works out to $43.67 and rounds to $44.
This spread highlights real differences of opinion. Bulls at Citi see the turnaround and margin recovery supporting a higher valuation, while bears at Bank of America highlight growing price sensitivity and a softer revenue outlook. Recent moves reflect the divide: UBS lowered its target from $38 to $33 in early November 2026, whereas BMO held steady at $40 with an Outperform rating around the same time.
Shares recently traded near $34.72, so a move to $44 implies upside of roughly 27% — a meaningful but achievable gain for a mid-cap apparel name. The 52-week range of roughly $27 to $44 puts the target at the upper boundary of recent trading.
Progress hinges on sustaining recent profitability improvements. Carter's posted second-quarter fiscal 2026 revenue of about $615 million, up roughly 5% year over year and ahead of estimates, with adjusted EPS of $0.26 versus expectations near $0.06 and an operating margin of about 22.7%. Management has guided to full-year net sales growth of only 2% to 3%, however, and a third-quarter beat came with a softer revenue outlook.
The $44 area lines up with the stock's 52-week high zone, making it both a natural price objective and a likely resistance level. A durable support level sits near the $27 to $28 zone, near the 52-week low and the more bearish analyst targets. Between these levels the stock has formed a wide trading range, and any sustained advance toward the upper bound would require a breakout above prior highs rather than a continuation of recent range-bound action.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms do not always state one explicitly and horizons can vary. Investors should watch the next quarterly earnings report and guidance for evidence on whether margin gains and retail momentum are holding, any further analyst target revisions, wholesale order trends, and consumer spending data. Tariff-policy and cost developments also remain relevant to a company still navigating a challenged retail backdrop.
Can Carter's stock reach $44? The figure is not a full consensus but the average of the three verified analyst targets above the current price — Citi's $53, BMO's $40, and Goldman Sachs' $38. Reaching it would require a rise of roughly 27% from recent levels near $34.72. The bullish case rests on a dramatic margin recovery, recovered tariff proceeds, and an undemanding valuation, while the bearish case centers on soft guidance, wholesale headwinds, and a handful of targets below the current price. With the full target range spanning $26 to $53, the honest answer is that the outcome depends on whether the turnaround proves durable — a question that upcoming earnings, guidance, and analyst revisions will help resolve.
In my own work, Tickeron's AI Daily Buy/Sell Signals provide a useful layer of objective input. The system monitors thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. For a name like Carter's that sits in a wide trading range, these signals help flag potential shifts alongside fundamental analysis without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CRI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 62 cases where CRI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CRI as a result. In 60 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for CRI just turned positive on November 04, 2026. Looking at past instances where CRI's MACD turned positive, the stock continued to rise in 38 of 56 cases over the following month. The odds of a continued upward trend are 68%.
The 10-day moving average for CRI crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRI advanced for three days, in 194 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 117 of 189 cases where CRI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
CRI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.144) is normal, around the industry mean (1.858). P/E Ratio (5.972) is within average values for comparable stocks, (12.576). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (0.517). Dividend Yield (0.031) settles around the average of (0.067) among similar stocks. P/S Ratio (0.346) is also within normal values, averaging (0.652).
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. CRI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of apparel and related products for babies and young children
Industry ApparelFootwearRetail